“This is the first study that actually looked at a relatively large number of patients for whether there is any neuroprotective effect in Alzheimer’s disease,” Edison said.
The trial enrolled predominantly people with mild Alzheimer’s disease, measured by a test known as the Mini-Mental State Examination, a scale that goes up to 30.
The GLP-1 drug class also includes Eli Lilly’s Mounjaro and Zepbound, which use the active ingredient tirzepatide, which mimics not just the hormone GLP-1 but another called GIP.
But it hasn’t announced any trials of its GLP-1 drugs in Alzheimer’s.
GLP-1 drugs can have side effects, though, primarily gastrointestinal problems like nausea and vomiting.
Persons:
liraglutide, “, ”, Maria Carrillo, Carrillo, Paul Edison, ” Edison, Edison, Eli Lilly’s Mounjaro, Alzheimer’s Lilly, hasn’t, Lilly, Lars Fruergaard Jorgensen, there’s, Dr, Sanjay Gupta, semaglutide
Organizations:
CNN, Alzheimer’s Association International Conference, Alzheimer’s Association, Novo Nordisk, Imperial College London, ”, Nordisk, ” Novo Nordisk, CNN Health, University of Oxford, Alzheimer’s Society, Alzheimer’s
Locations:
United Kingdom, Philadelphia, Alzheimer’s, ” Novo, Danish